Boehringer Ingelheim and Eli Lilly launch linagliptin trial

1 August 2013

German family-owned drug major Boehringer Ingelheim and US pharma major Eli Lilly (NYSE: LLY) have enrolled the first patient in a new cardiovascular and renal outcomes trial for Trajenta (linagliptin) in type 2 diabetes.

The CARMELINA (CArdiovascular safety and RenalMicrovascular outcomE with LINAgliptin in patients with Type 2 Diabetes mellitus at high vascular risk) trial will investigate the once-daily dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, on cardiovascular and renal microvascular outcomes in adults with type 2 diabetes at risk of cardiovascular and renal events.

Linagliptin (marketed in Europe as Trajenta and in the USA as Tradjenta) is used along with diet and exercise and other drug therapies to improve glycemic control in adults with Type 2 Diabetes.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK